These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 32619005

  • 1. De novo Anti-TNF-α-induced Congestive Heart Failure in a Patient With Turner Syndrome and Crohn's Disease.
    Keating E, Kelleher TB, Lahiff C.
    Inflamm Bowel Dis; 2020 Nov 19; 26(12):e161-e162. PubMed ID: 32619005
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Concurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease.
    Adusumilli N, Aronica J, Glass F, Friedman A.
    J Drugs Dermatol; 2022 Nov 01; 21(11):1256-1257. PubMed ID: 36342727
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pustular lesions in patients with Crohn disease and treatment with tumour necrosis factor-α inhibitors.
    Balaguer-Franch I, Hernández de la Torre-Ruiz E, Lacasta-Plasin C, García-Piqueras P, Menchén-Viso L, Baniandrés-Rodríguez O.
    Clin Exp Dermatol; 2022 Feb 01; 47(2):453-455. PubMed ID: 34431537
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. IgA nephropathy in a child: Crohn's disease-associated or adalimumab induced?
    Graziano F, Busè M, Cassata N, Lentini VL, Citrano M.
    Curr Med Res Opin; 2022 Jan 01; 38(1):139-143. PubMed ID: 34866503
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Occurrence of Sweet syndrome under anti-TNF.
    Banse C, Sobocinski V, Savoye G, Avenel G, Vittecoq O.
    Clin Rheumatol; 2015 Nov 01; 34(11):1993-4. PubMed ID: 26292633
    [Abstract] [Full Text] [Related]

  • 13. Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text].
    Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C.
    J Cutan Med Surg; 2020 Nov 01; 24(4):333-339. PubMed ID: 32527153
    [Abstract] [Full Text] [Related]

  • 14. Eosinophilic Fasciitis in a Patient With Crohn's Disease Treated With Infliximab. A Rare Coexistence or a Drug-related Manifestation?
    Mpitouli A, Kougkas N, Avgoustidis N, Ergazakis N, Karmiris K.
    Inflamm Bowel Dis; 2020 Jul 17; 26(8):e77-e78. PubMed ID: 32529216
    [No Abstract] [Full Text] [Related]

  • 15. Severe Necrotising Toxoplasmic Retinochoroiditis in a Patient With Crohn's Disease in Use of Adalimumab and Azathioprine.
    Biancardi AL, Costa JB, de Azevedo LGB, de Moraes HV, Barroso PF, Zaltman C.
    Inflamm Bowel Dis; 2020 Jun 18; 26(7):e69-e70. PubMed ID: 32415301
    [No Abstract] [Full Text] [Related]

  • 16. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn's Disease.
    Loebenstein M, Schulberg JD.
    Gastroenterology; 2020 Jun 18; 158(8):2069-2071. PubMed ID: 31945355
    [No Abstract] [Full Text] [Related]

  • 17. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H.
    J Gastroenterol Hepatol; 2019 Aug 18; 34(8):1329-1336. PubMed ID: 30724387
    [Abstract] [Full Text] [Related]

  • 18. Cerebral Vasculitis in Crohn's Disease: Always a Complication of Inflammatory Bowel Disease or Tumor Necrosis Factor-Alpha Inhibition?
    Moser T, Bubel NE, Machegger L, Pikija S, Sellner J.
    Inflamm Bowel Dis; 2019 Nov 14; 25(12):e160-e161. PubMed ID: 31560743
    [No Abstract] [Full Text] [Related]

  • 19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 20. Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy.
    Takahashi G, Kobayashi H, Saito Y, Ohsawa S, Suzuki K, Ishihara S, Hisada T.
    Intern Med; 2019 Dec 15; 58(24):3593-3596. PubMed ID: 31434822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.